Introduction
Epidemiologic observation data for autoimmune and inflammatory diseases (AID) have long supported the hypothesis that AID share an underlying genetic basis in common. First, AID have been observed to cluster in families [1, 2] and second, they co-occur in the same individuals at a rate higher than expected by chance [3 ] . An obvious component of this co-occurrence is owing to the influence of shared HLA haplotypes; because variation at this locus cannot explain all of familial risk, other genetic determinants must also be shared in complex patterns of overlap [4] . However, these data have not completely explained the underlying shared biological basis of disease; the recent large-scale identification of genetic AID risk variants promises to change this.
Over the past five years, the genetics of AID have significantly advanced, with association at convincing levels of statistical significance [5] at over 200 common or rare variants [6] . These discoveries have been driven largely by genome-wide association studies (GWAS), whose aim is to test association between common genetic variation at hundreds of thousands of markers and a disease endpoint; in these studies, thousands of individuals are typically characterized [7] . Across the spectrum of AID, application of a range of informatics algorithms has generated plausible hypotheses about the causal genes and tissues underlying disease pathogenesis, motivating functional experiments designed to test these hypotheses [8 ,9,10] .
One clear observation is that a large fraction of associations at genome-wide levels of significance in one AID also relate to additional AID [11 ] . While some shared biology might have been expected [3] , the magnitude (>40% of loci) and precision of commonality was not. Several interesting and compelling observations have emerged implicating several genes with shared etiology: beyond the well-described examples at the MHC [12] and PTPN22 (see below) loci, associations near STAT3 (discussed below) and SH2B3 [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , amongst others appear to harbor shared risk variants. The latter is particularly intriguing as it is thought to be a T cell receptor adaptor (if indeed it is the relevant gene in the region), there are associations to many traits beyond immune disease such as coronary artery disease and blood pressure measurements and there is strong evidence of positive selection in the region [23] .
A credible hypothesis that follows from the genetic data is that etiological mechanisms and pathways contributing susceptibility to multiple AID are shared among them. To address the critical aim of identifying pathways that are either shared across diseases or are unique to specific ones, it is essential to develop network models for commonalities, and consider how genetic association data might be used to distinguish between such models.
Here, we first review the evidence for a shared genetic architecture for AID, outline models for shared pathways, the underlying hypotheses for them, how such models can be generated and validated, and the implication for our understanding of disease pathogenesis.
Genetic studies of AID highlight common pathways underlying disease human genome, which satisfy stringent statistical criteria and have been replicated across multiple cohorts. This now includes >420 associations to >35 common, complex autoimmune or inflammatory diseases or quantitative measures related to immune function [6] . A biological interpretation and hypothesis generation is only now beginning (see accompanying reviews by Graham; Xavier; and Gregersen and Plenge in this issue).
As more associations have been reported, a substantial overlap between AID has emerged [22] , with independent studies in individual diseases finding associations to the same genomic regions (for example, the region encoding TNFAIP3 on human chromosome 6 [24] [25] [26] ). This has motivated several meta-analyses across pairs of diseases to establish their shared genetic basis: for example, celiac disease has been compared to rheumatoid arthritis [27] , type 1 diabetes [28] and Crohn's disease [29] and in each case substantial locus overlap has been observed suggesting shared underlying pathogenesis. These observations very probably underestimate the actual extent of commonality, as individual studies lack statistical power to detect all true associations at genome-wide significance: Stahl et al. [30 ] estimate that in several diseases where GWAS has been successful hundreds of further associations remain to be found. This problem compounds when considering independent discoveries across diseases, as power is multiplicative across studies. This means that, if an association is true in two diseases, the power to find it in both is the product of the power of each individual study. Therefore, estimates of the true extent of genetic sharing are probably underestimated by either simple overlaps or pairwise meta-analyses.
One common goal in genetic mapping studies is to identify the causal variant(s) and haplotypes driving genetic susceptibility in each region of association. The most associated marker in a locus may simply be tightly linked to an unassayed, causal variant, so maximal association is insufficient evidence of causality for variants. Another goal is to identify the causal gene implicated in disease pathogenesis: regions found to associate with traits often harbor multiple genes, requiring refinement before inferences on genetic mechanisms and etiological causes of disease can be made [31] . To accomplish both goals, the AID community has developed shared resources, including the Immunochip, a common platform for fine-mapping AID-associated loci [32, 33] as well as computational approaches to select the likeliest candidate genes from regions of association [34,35 ,36 ].
To circumvent this limitation, we developed a statistical approach to detect such simultaneous associations [11 ] . Using GWAS data contributed by consortia studying celiac disease, Crohn's disease, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus and type 1 diabetes, we have shown that 47 of 107 markers (44%) known to be associated to one AID are enriched for association to multiple -but not all seven -diseases. Grouping these loci by which diseases they mediate risk to revealed significant structure: groups of loci appear to influence susceptibility to the same subsets of diseases. Furthermore, the genes in these loci encode proteins which interact more often than expected by chance [8 ] generating the hypothesis that risk variants perturb biological processes which mediate risk to several diseases.
Three obstacles hamper inferring pathogenic mechanisms shared across diseases from GWAS data. First, as discussed above, the level of precision in genetic mapping, in many cases, has not yet unambiguously identified causal variants. Thus, it is challenging to distinguish between genetic effects genuinely shared between diseases and independent risk variants residing in the same region of the genome. We illustrate this in Figure 1 , where we present the strongest associations for multiple diseases to the locus on 6q23 encoding the candidate gene TNFAIP3. To resolve this first issue, the AID community is freely exchanging genetic data across disease areas, which now allows the development of new statistical approaches to resolve this ambiguity.
Second, increasingly precise functional maps of immune cell subsets are required. The maps will provide a resource by which the genes to pathways mapping can be inferred, and in which specific cells susceptibility to disease is determined. Genomic technologies are particularly attractive for such maps as they are amenable to automation, throughput and industrial process standards. The limiting factor is the careful acquisition of samples: rigorous standards in statistical experimental design, cell isolation, flow sorting and sample preparation are required to avoid the limitations which have hampered previous such efforts. Such experiments in highly parallel gene expression have begun, with several large-scale projects aiming to characterize lymphocyte populations currently underway (for example, GTEx [commonfund.nih.gov/GTEx/Publications.aspx] and ImmVar [www.immvar.org]). Other measurements (DNse I hypersensitivity [37] , nucleotide methylation status by sequencing [38] , chromatin immunoprecipitation and sequencing [39] and many others) are equally valuable and capture different types of information. With gene expression, for example, one can assess whether disease risk variants alter gene expression suggesting a mechanism of action [40 ] . Similar inferences can be made from other technologies. Far more exciting is the prospect of using these data in bulk to infer gene regulatory programs for groups of risk variants that may cumulatively perturb pathways, a topic of much current research interest.
The third issue is one of interpretation: several risk alleles appear to impart risk to some diseases but are protective of others [41 ,42] and it remains unclear how this evidence should be incorporated into a pathway view of disease. A well-known example in the literature is the R620W variant in PTPN22, known to confer risk to T1D [43] and the development of autoantibodies [20] , RA [44] and vitiligo [45] , but to be protective for Crohn's disease [46] . Another emerging example is the rs744166 polymorphism in an intron of STAT3 on chromosome 17, where the A allele confers risk to Crohn's disease [46] and the G allele to multiple sclerosis [47] . It is at present unclear whether this is a feature specific to inflammatory bowel disease. We discuss some possible explanations for these opposing risk effects in the following section. However, we can begin to outline shared pathway architecture from extant information. Under the assumption that, in each disease, causal variants perturb a limited number of cellular processes, pathway enrichment analysis [48, 49] and functional genomics datasets can be queried to reveal pathway components that are preferentially encoded in associated loci. These approaches have shown that this cumulative burden hypothesis is true [36 ] , which argues that susceptibility alleles accumulate and perturb pathways to influence susceptibility (see Cotsapas and Hafler [50] for more discussion on this point). These approaches can be expanded to incorporate genetic data from multiple diseases in much the same fashion [11 ] . We next discuss various models of how risk variants may congregate in shared pathways. These have implications not only for the development of methods to detect such architectures, but also the design of experiments to uncover the precise biological activities being perturbed.
Models for common AID pathways
Given the cumulative burden hypothesis, we consider models for how common pathways might be organized biologically. This is crucial because patterns of association in human genetic data across diseases could be used directly to evaluate which models (if any) apply, and the biological contexts in which they operate in practice. This will be required to devise precise, functional experiments aiming to uncover the biological processes and mechanisms that contribute to one or multiple AID. Figure 2 ), perturbed by risk variants. The simplest arrangement is that a network is either private to a single disease or common to more than one. In this model, genetic variants perturbing a private network will only modify risk to one disease; those perturbing a shared network will associate to all those diseases (Figure 2a) . At least some AID networks appear to have this discrete structure [11 ] : the IL23R signaling network appears to mediate risk to multiple diseases in this fashion, although this has yet to be conclusively shown [51] . Multiple disease associations at 6q23 do not clearly identify shared genetic effects. We show the location and magnitude of reported associations for RA [26] , celiac disease [52] , SLE [24] , psoriasis [25] and multiple sclerosis [53] . It is impossible to infer shared vs. distinct associations from these data: the variants associated to RA, SLE and psoriasis in the TNFAIP3 (also known as A20) coding region itself may point to a shared effect, as may the RA and celiac associations in the center of the region. Whether these two blocks are distinct is also unclear. These ambiguities -common to many locican only be resolved by global analysis of all diseases.
Alternative arrangements are where a shared pathway is modified by risk variants for multiple diseases essentially at random (Figure 2b ) or where a modular architecture connects disease-specific pathways to a shared hub (Figure 2c,d ). In the first view, any variant may predispose to one or more diseases, but the cumulative load on the pathway influences multiple outcomes. In the others, disease-specific variants act on peripheral modules of the pathway to further elevate risk to that disease, but not to others. In this configuration, it is possible that each of these modules are active in different cells or respond to different stimuli, but the higher-order structure is required for pathogenesis. This poses great challenges for experimentation and will possibly require development of new, systems-level immunological approaches to decipher correctly.
A consideration of susceptibility and protective effects across diseases as discussed above can neatly operate in the above framework. Biologically, there is no requirement that pathways contributing susceptibility to multiple diseases do so in the same place at the same time. For example, higher expression of an important gene in one tissue could contribute susceptibility for one disease, but this increase in expression protects for another in a different tissue. This may be mediated either by the same pathways in both tissues, or by different ones if the gene participates in multiple processes. Contextualizing these observations will be particularly important to address experimentally for opposite effect variants and the genes they act on. In reality, we expect multiple pathways and networks to contribute to pathogenesis and no particular model to dominate. Delineating the structure of biological networks contributing shared and distinct liability to AID provides one opportunity by which the key cellular components and mechanisms implicated in disease can be identified. After those processes are identified, this approach will also help to target the most tractable to take forward for functional experimentation in order to verify the underpinnings that contribute to AID susceptibility.
Conclusion
Has the investment in AID GWAS been a good one? We answer unambiguously in the affirmative: the landscape of spectacular shared genetic liability across multiple AID could not have been expected based on previous genetic, epidemiological, or clinical information. Because of this unexpectedly clear observation supporting shared mechanisms contributing to disease, and because of the accessibility of many relevant cellular models, immunemediated traits are uniquely poised to uncover numerous biological and mechanistic insights. Furthermore, if the Pathways and mechanisms in autoimmunity Voight and Cotsapas 555 biological underpinnings are in fact shared, discoveries in one model or system have the potential to translate quickly into others, thereby exponentially increasing the pace of discovery. We believe that the systematic dissection of multiple trait associations using genetic, genomic and immunological tools will result in rapid translation of discoveries from GWAS into biologically actionable information for functional studies and therapeutic efforts.
